Risk of Infection from Human- or Animal-Derived Raw Materials
First written in FY2017. 3 of 4 entries say "Restated". Latest entry: FY2023.
3 other companies' latest entry also says "Restated".
- FY2023RestatedAnnual report
「The Group's regenerative cell medicines use human cells and tissues, and safety risks are said to exist because the risk of infection originating from the human cells and tissues used cannot be completely eliminated.」
The risks of infection and harm from unknown viruses attributable to human cells and tissues and animal-derived raw materials have been reaffirmed. - FY2020RestatedAnnual report
「The Group's regenerative cell medicines carry risks associated with the implantation into patients of human- or animal-derived materials used as raw materials, including the risk of infection attributable to such materials. The possibility that these risks could have a material impact on the Group's business and financial position cannot be ruled out.」
The risks of infection and harm from unknown viruses attributable to human cells and tissues and animal-derived raw materials have been reaffirmed. - FY2019RestatedAnnual report
「The Group's regenerative cell medicines carry risks associated with the implantation into patients of human- or animal-derived materials used as raw materials, including the risk of infection attributable to such materials. The possibility that these risks could have a material impact on the Group's business and financial position cannot be ruled out.」
The risks of infection and harm from unknown viruses attributable to human cells and tissues and animal-derived raw materials have been reaffirmed. - FY2017First statedAnnual report
「The Group's regenerative cell medicines carry risks associated with the implantation into patients of human- or animal-derived materials used as raw materials, including the risk of infection attributable to such materials. The possibility that these risks could have a material impact on the Group's business and financial position cannot be ruled out.」
The Company discloses the possibility of infection and harm from unknown viruses attributable to human cells and tissues and animal-derived raw materials.